Hematological differences between patients with different subtypes of sickle cell disease on hydroxyurea treatment by Neves, Fabia et al.
  Universidade de São Paulo
 
2012
 
Hematological differences between patients
with different subtypes of sickle cell disease on
hydroxyurea treatment
 
 
Rev. Bras. Hematol. Hemoter.,v.34,n.6,p.426-429,2012
http://www.producao.usp.br/handle/BDPI/40013
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Sem comunidade Scielo
Original Article
426 Rev Bras Hematol Hemoter. 2012;34(6):426-9
Hematological differences between patients with different subtypes of sickle cell disease on 
hydroxyurea treatment
Fabia Neves 
Osvaldo Alves Menezes Neto 
Larissa Bueno Polis 
Sarah Cristina Bassi 
Denise Menezes Brunetta 
Ana Cristina Silva-Pinto 
Ivan Lucena Angulo 
Hospital das Clínicas da Faculdade de 
Medicina de Ribeirão Preto,  Universidade  
de São Paulo -  USP, Ribeirão Preto, SP, Brazil
Conflict-of-interest disclosure:
The authors declare no competing financial 
interest
Submitted: 4/8/2012
Accepted: 7/31/2012
Corresponding author:
Ivan Lucena Angulo
Hemocentro - Hospital das Clínicas da 
Faculdade de Medicina de Ribeirão Preto da 
Universidade de São Paulo - HC FMRP USP
R Ten Catão Roxo – 2501, Monte Alegre 
14.051-140 Ribeirão Preto, SP, Brazil
ilangulo@uol.com.br
www.rbhh.org or www.scielo.br/rbhh
DOI: 10.5581/1516-8484.20120107
Introduction 
Silvestroni and Bianco first described the S/Beta thalassemia association in Italy, in 
1944(1). In Brazil, the first study on clinical, hematological and genetic characteristics of 
this association was performed in Ribeirão Preto by Zago et al.(2). The hematological data 
provide elements to differentiate between S/Beta thalassemia and homozygous S (SS) as with 
S/Beta thalassemia, patients present microcytosis and hypochromia seen by the low values of 
mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), fetal hemoglobin 
increase (Hb F) and hemoglobin (Hb) A2. The clinical progression is similar, although there 
are associations with benign mutations of thalassemia. The benefits resulting from treatment 
with hydroxyurea (HU) in patients with sickle cell disease are undeniable(3) in particular 
for SS and S/Beta thalassemia individuals. Considering this, its use is highly recommended for 
patients with poor prognoses, which constitutes most affected individuals. Several studies(4-9) 
have shown the benefits of HU in subjects with severe (β0) or less severe (β+) thalassemia 
mutations combined with Hb S. It remains to be proven whether HU can be extended to adult 
carriers of Hb SC, Hb SD associations and others; the results are favorable in children(10). 
Studies on S/Beta thalassemia are scarce due to the small number of patients and the 
reduced candidate group for HU treatment. The association with Beta thalassemia attenuates 
some aspects of the disease in some patients and an unfavorable clinical evolution, such as 
vaso-occlusive crisis (VOC), acute chest syndrome (ACS), several hospitalizations etc., is 
necessary to prescribe HU. Treatment using HU in S/Beta thalassemia was tested in Greek 
patients(4) simultaneously with the Multicenter Study of HU in sickle cell anemia(3). Most of the 
patients presented clinical improvement and increases in hematological values over the long 
term. In a later review, effects in children with S/Beta thalassemia(5) were observed. Another 
study found premature hematological alterations (4 weeks)(6), and in a more recent study(7) the 
hematological response was significant after six months of HU treatment. In Sicily(8), S/Beta 
thalassemia patients with poor evolution were studied and there was evident clinical improvement 
with increases in MCV but without increases in Hb levels and with few significant adverse 
effects. The largest prospective study on survival in S/Beta thalassemia patients(9) showed a 
great reduction in clinical complications and increases in survival compared to patients who 
were not treated with HU, thus consolidating the significant benefits of the drug in this sickle 
cell syndrome. A prospective study on the action of HU in sickle cell anemia(11) showed early 
hematological alterations that constitute an easy manner to measure the action of the drug, thus 
electing the complete blood count as the best test to monitor toxicity and adherence. 
Since 1999, sickle cell disease and HU treatment has been studied in Ribeirão Preto, Brazil. 
The different hematological values in homozygous S and S/Beta thalassemia patients led to a 
Objective: Sickle cell anemia and the interaction S/Beta thalassemia differ in hematological values due to 
microcytosis and hypochromia caused by the thalassemic mutation. The clinical benefit of long-term hydroxyurea 
treatment is undeniable in sickle cell disease with monitoring of the biological action of the drug being by the 
complete blood count. The objective of this work is to compare changes in some of the erythrocytic indexes 
between S/Beta thalassemia and sickle cell anemia patients on long-term hydroxyurea treatment.
Methods: The values of erythrocyte indexes (mean corpuscular volume and mean corpuscular hemoglobin) 
were compared in a retrospective study of two groups of patients (Sickle cell anemia and S/Beta thalassemia) on 
hydroxyurea treatment over a mean of six years.
Results: The quantitative values of the two parameters differed between the groups. Increases in mean 
corpuscular volume and reductions in mean corpuscular hemoglobin delay longer in S/Beta thalassemia 
patients (p-value = 0.018). 
Conclusion: Hematological changes are some of the beneficial effects of hydroxyurea in sickle cell disease 
as cellular hydration increases and the hemoglobin S concentration is reduced. The complete blood count is 
the best test to monitor changes, but the interpretation of the results in S/Beta thalassemia should be different.
Keywords: Anemia, sickle cell; Hydroxyurea; Hemoglobinopathies; Erythrocyte indices
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Table 1 - MCV (mean ± standard deviation) and increases after hydroxyurea treatment in sickle cell disease patients 
S/Beta thalassemia Hemoglobin SS p-value
MCV (fl) % increase (*) MCV (fl) % increase (*)
Basal 77.0 ± 10.5 0 91.8 ± 9.9 0 < 0.0001
3 months 90.6 ± 24.5 +17.6 104.9 ± 30.6 +14.2 0.013
6 months 96.5 ± 27.6 +25.3 105.9 ± 26.2 +15.3 0.0259 
12 months 98.6 ± 16.4 +28.0 106.6 ± 28.0 +16.1 0.0538
Current 104.8 ± 14.0 +36.0 116.1 ± 14.1 +26.4 0.0020
*Percentage increase S/Beta thalassemia vs. SS – p-value = 0.018
Table 2 - MCH concentrations (mean ± standard deviation) and changes after hydroxyurea treatment in sickle cell patients 
S/Beta thalassemia Hemoglobin SS p-valueMCH g/dL % change * MCH g/dL % change *
Basal 32.2 ± 2.3 0 33.2 ± 2.0 0 ns
3 months 31.9 ± 2.0 -0.9 33.5 ± 2.0 +0.6 0.0168
6 months 32.0 ± 1.8 -0.6 33.2 ± 1.8 0 ns
12 months 32.2 ± 1.9 0 32.9 ± 1.6 -1.2 ns
Current 30.7 ± 1.5 -4.6 32.1 ± 1.3 -3.6 0.0031
*Percentage change S/Beta thalassemia vs. SS – p-value not significant,  ns: non-significant
comparative study of HU response between these two groups, in 
particular in respect to MCV, which has been used to evaluate the 
biological action of HU and patient adherence to treatment.
Methods 
A retrospective study was performed of 57 patients with 
sickle cell disease allocated to two groups: S/Beta0 and S/Beta+ 
thalassemia (S/Beta Group) and homozygous S (sickle cell 
anemia – SS Group). The diagnoses were made from the results 
of hemoglobin studies by alkaline pH electrophoresis and 
high-performance liquid chromatography and when possible by 
a familial study, characterizing either homozygous S (carriers 
of hemoglobin S with normal A2 values) or S/Beta thalassemia 
(carriers of hemoglobin S with increased A2 values). All patients 
took HU for a period of one to 11 years (mean six years) for several 
complications of the disease. The hematological indexes, i.e., 
total hemoglobin, total leukocyte count, neutrophils and platelets, 
MCV and the MCH concentration, were closely monitored. The 
values were checked each month and recorded in the third, sixth 
and 12th months during HU treatment and a current measurement 
(July, 2010) after 1 to 11 years. Regular doses of folate were 
administered and Vitamin B12 was dosed at least once, thus 
discarding the possibility of other causes of macrocytosis. 
Although several patients had sporadic erythrocyte transfusions 
during the study period, the recorded values were not influenced 
by the transfusions. All the SS and S/Beta0 thalassemia patients 
received prophylactic penicillin regularly. The Kruskal-Wallis 
test was used for the statistical analysis of the paired nonparametric 
values between the S/Beta thalassemia and SS groups and the 
Mann Whitney test was used to compare values between the third, 
sixth and 12th months and current values in relation to the basal 
measurements. Significance was set for a two-tailed p-value < 0.05. 
Total Hb and Hb F values, basal and after 12 months of HU 
treatment were compared in both groups using the Wilcoxon 
test of the Prism 5 GraphPad program for Windows (GraphPad 
Software, Inc. 2012). The paired t-test (Excel v 12.1.1. 2008 for 
Mac) was used to analyze alterations in the MCV and MCH. 
Results
The S/Beta Group was composed of 11 male and seven 
female patients with a mean age of 23.8 ± 8.6 years (range: 
9-43 years old) and a mean HU dose of 24.7 ± 5.8 mg/kg/day. 
The means and standard deviations of Hb F varied from 
5.5 ± 6.22% (range: 0.1-20.0%) before HU treatment to 
21.1 ± 12.6% (range: 5.9-42.1%) after treatment (p-value = 0.0006) 
and total Hb ranged from 8.6 ± 1.4 g/dL (range: 6.1-11.3 g/dL) 
before to 9.5 ±1.5 g/dL (range: 7.1-12.5 g/dL) after 12 months of 
treatment (p-value = 0.0075).
The SS Group had 19 male and 20 female patients with a 
mean age 26.7 ± 10.5 years (range: 11-59 years old) and average 
dose of HU 24.07 ± 5.5 mg/kg/day. The Hb F varied from 
2.9 ± 2.1% (range: 0.5-8.4%) before HU treatment to 21.6 ± 7.4% 
(range: 7.4-34.5%) after treatment (p < 0.0001) and total 
hemoglobin varied from 8.4 ± 1.0 g/dL (range: 5.7-10.5 g/dL) 
before HU treatment to 9.2 ± 1.5 g/dL (range: 6.4-13.6 g/dL) after 
12 months of treatment (p-value = 0.0023).
The indications for HU use were VOC, priapism, severe 
hemolysis, pulmonary hypertension and ACS for both the S/Beta 
and SS Groups, besides heart failure and ischemic stroke. The 
incidence of VOC and ACS was higher, albeit not significantly, in 
the SS group (t-test, data not shown).
The results for MCV and MCH concentrations of the groups 
in the third, sixth, and 12th months and after the follow-up 
(more than 1 to 11 years) are shown in Tables 1 & 2 as absolute 
values and increases (+) or decreases (-). The mean length of HU 
treatment was statistically similar for both groups. 
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Discussion 
The hematological and cellular effects of HU treatment are 
expressed within the first weeks(11) with increases in total Hb, Hb 
F, MCH and MCV; in adults however, this is not always persistent 
during the entire treatment due to exhaustion of erythropoiesis. Once 
the medication is stopped, the hematological parameters return to the 
basal level after several months. The observed macrocytosis does not 
result from a lack of folate or vitamin B12, but from a rearrangement 
of the cellular protein synthesis. HU is an antimetabolite inhibitor 
of phase S (synthesis) of the cell cycle. Erythropoiesis occurs 
under tension due to the action of erythropoietin, which alters 
production to the fetal phase, producing gamma chains in the most 
primitive erythroblasts, which, along with alpha chains, produce 
Fetal Hb. More recently, the role of nitric oxide has been shown 
in hemoglobin synthesis where the guanosine monophosphate 
signaling system leads to the activation of the gamma-globulin gene 
(γ)(12,13). The result is an increase in volume and cellular hydration, 
which reduces the concentration of hemoglobin S. In addition, 
S/Beta thalassemia has free alpha chains that conjugate with gamma 
chains thus producing more Hb F. According, for some authors, 
this is one of the reasons that HU treatment is better in S/Beta 
thalassemia compared to SS patients(4,7,8).
In several studies there are overlapping results for 
SS and S/Beta thalassemia patients. Data referring only to 
S/Beta thalassemia are scarce. In 1995 Voskaridou(4) studied 14 
S/Beta thalassemia adults who had taken HU for 2 to 3 years. 
In 4 weeks they had presented great increases of Hb F, MCV 
and MCH, but this was lost over the long term. In the present 
study, as expected, patients presented increases in Hb F, total 
Hb and MCV in both groups, thus confirming the action of 
HU (with satisfactory adherence to treatment) in respect to 
sickle cell disease. Macrocytosis took longer to be expressed in 
S/Beta thalassemia due to microcytosis and hypochromia of the 
thalassemic cell population, which varies according to the beta 
gene mutation. The values of MCV in S/Beta thalassemia patients 
increased by 17.6% in three months, 25.3% in six months, 28% 
in 12 months and 36% after a mean follow-up of six years 
(p-value < 0.0001 in relation to the basal level). The values of 
MCV in SS individuals increased in the same periods by 14.2%, 
15.3%, 16.1% and 26.4%, respectively (p-value < 0.0001). These 
results show that the increase in MCV was more intense in 
S/Beta thalassemia patients compared to SS individuals 
(p-value = 0.018). The average MCV in S/Beta thalassemia only 
exceeds 100 fl after a long time (after 12 months), whereas the 
MCV in SS subjects reaches this value within 3 months (Table 1). 
There was no significant difference between the groups in respect 
to the MCH concentrations (Table 2). Despite the increases in Hb F 
and total Hb, the MCH concentration did not change significantly. 
The greater effectiveness of HU in S/Beta thalassemia does not 
seem to be linked to the lower MCH concentration, which would 
mean a lower possibility of polymerization and, consequently 
sickling. in 1997, Rogers(5), reporting on two children with 
S/Beta thalassemia being treated with doses of HU lower than 
the maximum tolerated, showed that the clinical improvement 
is similar to SS patients, as is the increase in Hb F and MCV. 
Koren(6) studied 19 children and adults but did not separate S/Beta 
thalassemia and SS patients. The study of Loukopoulos et al. of 
55 S/Beta thalassemia and 14 SS Greeks stratified in SS, S/Beta0 
thalassemia and S/Beta+ thalassemia Groups, showed increases in 
the total Hb and percentage of Hb F(7). The authors found, at the 
end of the study with a maximum dose of 1.5 g/day HU, increases 
in total Hb in the SS and S/Beta0 thalassemia Groups, but not in 
the S/Beta+ thalassemia Group, and increases in the percentage of 
Hb F in all groups (p-value < 0.001). The data of the current study, 
without separating S/Beta+ thalassemia and S/Beta0 thalassemia, 
demonstrated increases in the total Hb and Hb F in both groups 
with HU doses similar to the study of Loukopoulos et al.
Loukopoulos et al. also found significant increases in MCV 
for all groups (26 fl - SS, 28.8 fl - S/Beta0 thalassemia and 20.8 fl 
- S/Beta+ thalassemia). The data of the current study differ from 
the study of Loukopoulos in respect to the MCH concentration, as 
there was a reduction, albeit not significant, in S/Beta0 thalassemia 
patients. The explanation might be the different degree of suspension 
of the beta globin synthesis with mutations present in the Greek(7) 
(Caucasians) and Brazilian (mixed race) populations. The Brazilian 
population of S/Beta thalassemia might have benign African 
mutations(2,14-17) besides the classical Mediterranean ones. In the 
Mediterranean region, two-thirds of the population with sickle cell 
disease is composed of S/Beta thalassemia with severe mutations in 
contrast to the Brazilian population with an absolute predominance 
of homozygous S. The study by Rigano(8) of 22 S/Beta thalassemia 
individuals showed a significant increase (p-value < 0.001) in Hb F 
and MCV after HU treatment, which increased from 73.1 fl to 96.4 
fl (+ 23.3 fl) by the end of the study. No differences were seen in the 
levels of total Hb and total leukocytes. This author as well as others(4,7) 
emphasizes the better effect of HU in S/Beta thalassemia disease. 
The LaSHS study(9), which focused on survival, did not separate the 
SS and S/Beta thalassemia Groups in respect to MCV, but confirmed 
the great benefit of the HU in 295 S/Beta thalassemia patients, with 
MCV levels increasing from 54% to 87% (S/Beta0) and from 66% to 
82% (S/Beta+) after 10 years of continuous use. The limitations of the 
current study were that the mutations, the alpha:beta chain ratio and 
the presence of alpha thalassemia(18), which may change the globular 
index were not identified, and other possible causes of macrocytosis, 
such as bone marrow dysplasia, were not investigated. Moreover, 
the study population was small, while in the other studies(4,5,7,8), 93 
S/Beta thalassemia patients were analyzed.
Conclusion
Macrocytosis resulting from the action of HU in 
S/Beta thalassemia patients measured by MCV, is lower than 
that observed in homozygous S at 6 months of treatment 
but it reaches a comparative value after more than 1 year. 
Microcytosis and hypochromia due to the thalassemia mutation 
contribute to this effect. The MCH concentration does not 
reduce significantly, but it is higher in S/Beta thalassemia. 
These differences must be considered when evaluating 
adherence to HU treatment and the hematological effects of 
this drug in S/Beta thalassemia. Multicenter studies with more 
patients are necessary to accurately evaluate the hematological 
alterations with HU treatment in the different subtypes of 
sickle cell disease.
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